CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials

Rhea-AI Summary

CytoDyn Inc. (OTCQB: CYDY) will host a webcast on September 8, 2021, at 1:00 pm PT to discuss recent trial data, particularly from the mTNBC trials, and updates on COVID-19 and NASH trials. The management team, including CEO Nader Pourhassan and CMO Scott Kelly, will also address the status of the resubmission of the BLA for HIV. Participants are encouraged to submit questions in advance via email. The webcast will be available for listening on CytoDyn's corporate website and will be archived for 30 days after the event.

Positive

• Management will provide updates on multiple therapeutic indications, including mTNBC, COVID-19, and NASH trials.
• Webcast allows for direct interaction with the investment community, enhancing transparency.

Negative

• None.

VANCOUVER, Washington, Sept. 02, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Chief Operating Officer and Head of Clinical Development, will host an investment community webcast on Wednesday, September 8, 2021.

Management will provide an overview of the results from the recently reported data from the mTNBC trials, along with updates on COVID-19 and NASH trials, and the status of the resubmission of the BLA for HIV.

Management will provide approximately 60 minutes to address questions submitted online by analysts and investors.

Date:	Wednesday, September 8, 2021
Time:	1:00 pm PT / 4:00 pm ET
Dial-In:	None
Questions:

• Prior to the webcast, questions can be submitted online to ir@cytodyn.com.
• During the webcast, questions can be submitted through the webcast link below.

This is a “listen only” webcast, which can be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. Please note the below website will not be operational until approximately 60 minutes prior to the start of the webcast, which can be accessed via the following link:

https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/46521/indexl.html

The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until October 8, 2021.

CONTACTS

Investors:
Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com

FAQ

What is CytoDyn's upcoming webcast about?

CytoDyn's upcoming webcast on September 8, 2021, will discuss recent trial results and updates on the BLA resubmission for HIV.

Who will host the CytoDyn investment webcast?

The webcast will be hosted by Nader Pourhassan, Ph.D., Scott Kelly, M.D., and Christopher Recknor, M.D.

When is CytoDyn's investment community webcast scheduled?

The webcast is scheduled for September 8, 2021, at 1:00 pm PT / 4:00 pm ET.

How can investors submit questions for CytoDyn's webcast?

Investors can submit questions via email prior to the webcast or during the event through the webcast link.

Where can I access the recorded webcast from CytoDyn?

The recorded webcast will be available on CytoDyn's corporate website for 30 days after the event.